APOA2 and cholangiocarcinoma: Substantially lower levels of apoAII-ATQ or -AT (<1.0 μg/ml) were observed in samples from patients with IDACP, pancreatic diseases other than IDACP, cholangiocarcinoma, and duodenal carcinoma (Fig. 4B).